Liang Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1101095/publications.pdf

Version: 2024-02-01

56	6,694	172386	149623
papers	citations	29 h-index	56 g-index

58	58	58	10570
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Medicine, 2008, 14, 1351-1356.	15.2	1,238
2	A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nature Biotechnology, 2018, 36, 258-264.	9.4	1,066
3	LKB1 modulates lung cancer differentiation and metastasis. Nature, 2007, 448, 807-810.	13.7	907
4	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462, 1070-1074.	13.7	886
5	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 2006, 9, 485-495.	7.7	427
6	Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. Cancer Cell, 2007, 12, 81-93.	7.7	212
7	HER2 ^{YVMA} drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 474-479.	3.3	163
8	Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models. Cancer Research, 2007, 67, 4933-4939.	0.4	155
9	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 4973-4985.	3.2	141
10	A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice. Journal of Immunology, 2011, 186, 527-538.	0.4	128
11	Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8699-8704.	3.3	114
12	Cetuximab Response of Lung Cancerâ€“Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. Cancer Research, 2013, 73, 6770-6779.	0.4	87
13	Preparation of collagen/hydroxyapatite/alendronate hybrid hydrogels as potential scaffolds for bone regeneration. Colloids and Surfaces B: Biointerfaces, 2016, 143, 81-87.	2.5	85
14	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3978-E3986.	3.3	78
15	Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin. Clinical Cancer Research, 2008, 14, 6478-6486.	3.2	77
16	Epigenetic and Transcriptional Programs Lead to Default IFN-Î³ Production by Î³Î´ T Cells. Journal of Immunology, 2007, 178, 2730-2736.	0.4	66
17	Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase. Nature Nanotechnology, 2021, 16, 1150-1160.	15.6	62
18	Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Nonâ€“Small Cell Lung Cancer and Predict Strategies to Overcome Resistance. Clinical Cancer Research, 2014, 20, 1204-1211.	3.2	57

#	Article	IF	Citations
19	Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis, 2008, 29, 747-753.	1.3	47
20	Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation. PLoS ONE, 2014, 9, e95307.	1.1	47
21	Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. Nature Communications, 2019, 10, 1665.	5.8	45
22	Identification of urine protein biomarkers with the potential for early detection of lung cancer. Scientific Reports, 2015, 5, 11805.	1.6	44
23	Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget, 2016, 7, 69760-69769.	0.8	41
24	Blocking interaction between SHP2 and PDâ€1 denotes a novel opportunity for developing PDâ€1 inhibitors. EMBO Molecular Medicine, 2020, 12, e11571.	3.3	40
25	Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study. Frontiers in Oncology, 2019, 9, 550.	1.3	39
26	Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget, 2015, 6, 31313-31322.	0.8	38
27	In vitro evaluation of electrospun silk fibroin/nano-hydroxyapatite/BMP-2 scaffolds for bone regeneration. Journal of Biomaterials Science, Polymer Edition, 2017, 28, 257-270.	1.9	37
28	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget, 2016, 7, 3884-3896.	0.8	34
29	Phase separation of EML4â€“ALK in firing downstream signaling and promoting lung tumorigenesis. Cell Discovery, 2021, 7, 33.	3.1	34
30	Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Molecular Medicine, 2022, 14, e14502.	3.3	23
31	JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. European Journal of Immunology, 2007, 37, 818-829.	1.6	20
32	Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-ÎºB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Theranostics, 2020, 10, 11520-11534.	4.6	18
33	Urinary malate dehydrogenase 2 is a new biomarker for early detection of nonâ€smallâ€cell lung cancer. Cancer Science, 2021, 112, 2349-2360.	1.7	18
34	A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients. Theranostics, 2020, 10, 484-497.	4.6	17
35	Pharmaceutical applications of framework nucleic acids. Acta Pharmaceutica Sinica B, 2022, 12, 76-91.	5.7	16
36	FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression. Cell Proliferation, 2019, 52, e12553.	2.4	15

#	Article	IF	Citations
37	Discovery of Novel Inhibitor for WNT/Î²-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening. Molecules, 2020, 25, 1680.	1.7	15
38	IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function. Cell Cycle, 2019, 18, 3300-3312.	1.3	14
39	Strategies for developing PD-1 inhibitors and future directions. Biochemical Pharmacology, 2022, 202, 115113.	2.0	12
40	Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis. EBioMedicine, 2020, 53, 102689.	2.7	11
41	The impact of the MYB-NFIB fusion proto-oncogene in vivo. Oncotarget, 2016, 7, 31681-31688.	0.8	11
42	The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv. Cell Research, 2002, 12, 47-54.	5.7	10
43	Direct induction of neural progenitor cells transiently passes through a partially reprogrammed state. Biomaterials, 2017, 119, 53-67.	5.7	10
44	Three Years After Black Saturday. Journal of Burn Care and Research, 2017, 38, 334.	0.2	10
45	EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment. Oncotarget, 2016, 7, 3367-3378.	0.8	9
46	GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence. Frontiers in Oncology, 2020, 10, 824.	1.3	9
47	Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer. Theranostics, 2021, 11, 6592-6606.	4.6	9
48	A new ALK inhibitor overcomes resistance to firstâ€•and secondâ€generation inhibitors in NSCLC. EMBO Molecular Medicine, 2022, 14, e14296.	3.3	9
49	<italic>Mup</italic>-knockout mice generated through CRISPR/Cas9-mediated deletion for use in urinary protein analysis. Acta Biochimica Et Biophysica Sinica, 2016, 48, 468-473.	0.9	8
50	Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity. PLoS ONE, 2015, 10, e0123623.	1.1	6
51	The Development and Validity of the Adult Burn Outcome Questionnaire Short Form. Journal of Burn Care and Research, 2018, 39, 771-779.	0.2	6
52	Challenges to the Standardization of Trauma Data Collection in Burn, Traumatic Brain Injury, Spinal Cord Injury, and Other Trauma Populations: A Call for Common Data Elements for Acute and Longitudinal Trauma Databases. Archives of Physical Medicine and Rehabilitation, 2019, 100, 891-898.	0.5	6
53	Loss of hypermethylated in cancer 1 (HIC1) promotes lung cancer progression. Cellular Signalling, 2019, 53, 162-169.	1.7	6
54	TAZ inhibits glucocorticoid receptor and coordinates hepatic glucose homeostasis in normal physiological states. ELife, 2021, 10, .	2.8	6

#	Article	IF	Citations
55	Efficient Generation of Mice with Consistent Transgene Expression by FEEST. Scientific Reports, 2015, 5, 16284.	1.6	3
56	Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor. Oncotarget, 2015, 6, 31628-31639.	0.8	2